Details
Stereochemistry | ACHIRAL |
Molecular Formula | C8H11NO3 |
Molecular Weight | 169.1778 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(O)C(CO)=C(CO)C=N1
InChI
InChIKey=LXNHXLLTXMVWPM-UHFFFAOYSA-N
InChI=1S/C8H11NO3/c1-5-8(12)7(4-11)6(3-10)2-9-5/h2,10-12H,3-4H2,1H3
Molecular Formula | C8H11NO3 |
Molecular Weight | 169.1778 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB00165Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/pyridoxine-hydrochloride-injection.html
Sources: http://www.drugbank.ca/drugs/DB00165
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/pyridoxine-hydrochloride-injection.html
Pyridoxine is the 4-methanol form of vitamin B6 and is converted to pyridoxal 5-phosphate in the body. Vitamin B6 (pyridoxine) is a water-soluble vitamin used in the prophylaxis and treatment of vitamin B6 deficiency and peripheral neuropathy in those receiving isoniazid (isonicotinic acid hydrazide, INH). Vitamin B6 has been found to lower systolic and diastolic blood pressure in a small group of subjects with essential hypertension. Hypertension is another risk factor for atherosclerosis and coronary heart disease. Another study showed pyridoxine hydrochloride to inhibit ADP- or epinephrine-induced platelet aggregation and to lower total cholesterol levels and increase HDL-cholesterol levels, again in a small group of subjects. Vitamin B6, in the form of pyridoxal 5'-phosphate, was found to protect vascular endothelial cells in culture from injury by activated platelets. Endothelial injury and dysfunction are critical initiating events in the pathogenesis of atherosclerosis. Human studies have demonstrated that vitamin B6 deficiency affects cellular and humoral responses of the immune system. Vitamin B6 deficiency results in altered lymphocyte differentiation and maturation, reduced delayed-type hypersensitivity (DTH) responses, impaired antibody production, decreased lymphocyte proliferation and decreased interleukin (IL)-2 production, among other immunologic activities. Used for the treatment of vitamin B6 deficiency and for the prophylaxis of isoniazid-induced peripheral neuropathy.
CNS Activity
Originator
Sources: http://www.bendectin.com/en/
Curator's Comment: The combination of doxylamine and vitamin B6 (PYRIDOXINE) was first introduced to the US market as Bendectin in 1956 by the Wm. S. Merrell Company of Cincinnati, Ohio.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: WP408 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21944860 |
8.3 mM [Ki] | ||
Target ID: CHEMBL5960 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21462331 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | PYRIDOXINE HYDROCHLORIDE Approved UsePyridoxine Hydrochloride Injection is effective for the treatment of pyridoxine deficiency as seen in the following:
Inadequate dietary intake.
Drug-induced deficiency, as from isoniazid (INH) or oral contraceptives.
Inborn errors of metabolism, e.g., vitamin B6 dependent convulsions or vitamin B6 responsive anemia. Launch Date1972 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
372.7 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7988052/ |
100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PYRIDOXINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
2183.2 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7988052/ |
100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PYRIDOXAL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
892.9 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7988052/ |
100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PYRIDOXAL PHOSPHATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1750.3 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7988052/ |
100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
4-PYRIDOXIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
47.1 ng/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
58.9 ng/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXAL blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
30.1 ng/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXAL PHOSPHATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
48.2 ng/mL |
20 mg 2 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
189.6 ng/mL |
20 mg 2 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXAL blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
85.9 ng/mL |
20 mg 2 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXAL PHOSPHATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
38.9 ng/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
12.7 ng/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: HIGH-FAT |
|
62 ng/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXAL blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
33.1 ng/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXAL blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: HIGH-FAT |
|
27.4 ng/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXAL PHOSPHATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
30.2 ng/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXAL PHOSPHATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: HIGH-FAT |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2008.9 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7988052/ |
100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PYRIDOXINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
18603.4 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7988052/ |
100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PYRIDOXAL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
19420.2 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7988052/ |
100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PYRIDOXAL PHOSPHATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
18543.1 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7988052/ |
100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
4-PYRIDOXIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
42.5 ng × h/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
233.6 ng × h/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXAL blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
1076.2 ng × h/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXAL PHOSPHATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
80 ng × h/mL |
20 mg 2 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
1511.3 ng × h/mL |
20 mg 2 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXAL blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
1742.3 ng × h/mL |
20 mg 2 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXAL PHOSPHATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
35.1 ng × h/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
27 ng × h/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: HIGH-FAT |
|
244 ng × h/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXAL blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
249.2 ng × h/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXAL blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: HIGH-FAT |
|
1021.7 ng × h/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXAL PHOSPHATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
1064.6 ng × h/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXAL PHOSPHATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: HIGH-FAT |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.4 h |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
8 h |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXAL blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
0.4 h |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
1.2 h |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: HIGH-FAT |
|
8 h |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXAL blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
12.5 h |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXAL blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: HIGH-FAT |
Doses
Dose | Population | Adverse events |
---|---|---|
10 mg 2 times / day multiple, oral Recommended Dose: 10 mg, 2 times / day Route: oral Route: multiple Dose: 10 mg, 2 times / day Sources: |
pregnant, mean age 26 years Health Status: pregnant Age Group: mean age 26 years Sex: F Sources: |
Disc. AE: Somnolence, Syncope... AEs leading to discontinuation/dose reduction: Somnolence (1.5%) Sources: Syncope (0.7%) Dizziness (0.7%) |
117 mg multiple, oral Studied dose |
unhealthy, mean age 41.5 years Health Status: unhealthy Age Group: mean age 41.5 years Sex: F Sources: |
Disc. AE: Paraesthesia, Muscle weakness... AEs leading to discontinuation/dose reduction: Paraesthesia (34%) Sources: Muscle weakness (19.2%) Numbness (12.2%) |
175 mg multiple, oral Studied dose |
unhealthy, mean age 42 years Health Status: unhealthy Age Group: mean age 42 years Sex: F Sources: |
Disc. AE: Depression, Headache... AEs leading to discontinuation/dose reduction: Depression (79%) Sources: Headache (48%) Tiredness (59%) Irritability (38%) Neuropathy (40%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Dizziness | 0.7% Disc. AE |
10 mg 2 times / day multiple, oral Recommended Dose: 10 mg, 2 times / day Route: oral Route: multiple Dose: 10 mg, 2 times / day Sources: |
pregnant, mean age 26 years Health Status: pregnant Age Group: mean age 26 years Sex: F Sources: |
Syncope | 0.7% Disc. AE |
10 mg 2 times / day multiple, oral Recommended Dose: 10 mg, 2 times / day Route: oral Route: multiple Dose: 10 mg, 2 times / day Sources: |
pregnant, mean age 26 years Health Status: pregnant Age Group: mean age 26 years Sex: F Sources: |
Somnolence | 1.5% Disc. AE |
10 mg 2 times / day multiple, oral Recommended Dose: 10 mg, 2 times / day Route: oral Route: multiple Dose: 10 mg, 2 times / day Sources: |
pregnant, mean age 26 years Health Status: pregnant Age Group: mean age 26 years Sex: F Sources: |
Numbness | 12.2% Disc. AE |
117 mg multiple, oral Studied dose |
unhealthy, mean age 41.5 years Health Status: unhealthy Age Group: mean age 41.5 years Sex: F Sources: |
Muscle weakness | 19.2% Disc. AE |
117 mg multiple, oral Studied dose |
unhealthy, mean age 41.5 years Health Status: unhealthy Age Group: mean age 41.5 years Sex: F Sources: |
Paraesthesia | 34% Disc. AE |
117 mg multiple, oral Studied dose |
unhealthy, mean age 41.5 years Health Status: unhealthy Age Group: mean age 41.5 years Sex: F Sources: |
Irritability | 38% Disc. AE |
175 mg multiple, oral Studied dose |
unhealthy, mean age 42 years Health Status: unhealthy Age Group: mean age 42 years Sex: F Sources: |
Neuropathy | 40% Disc. AE |
175 mg multiple, oral Studied dose |
unhealthy, mean age 42 years Health Status: unhealthy Age Group: mean age 42 years Sex: F Sources: |
Headache | 48% Disc. AE |
175 mg multiple, oral Studied dose |
unhealthy, mean age 42 years Health Status: unhealthy Age Group: mean age 42 years Sex: F Sources: |
Tiredness | 59% Disc. AE |
175 mg multiple, oral Studied dose |
unhealthy, mean age 42 years Health Status: unhealthy Age Group: mean age 42 years Sex: F Sources: |
Depression | 79% Disc. AE |
175 mg multiple, oral Studied dose |
unhealthy, mean age 42 years Health Status: unhealthy Age Group: mean age 42 years Sex: F Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/19637937/ Page: 12.0 |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Acute isoniazid neurotoxicity during preventive therapy. | 2000 Feb |
|
[Evaluation of vitamin B6 and calcium pantothenate effectiveness on hair growth from clinical and trichographic aspects for treatment of diffuse alopecia in women]. | 2001 |
|
[Effects of biologically active supplements on the antioxidant and vitamin status of patients with hypertension and ischemic heart disease]. | 2001 |
|
Effects of vitamins on hepatic nuclear binding of L-tryptophan. | 2001 |
|
Influence of a probiotic yoghurt on the status of vitamins B(1), B(2) and B(6) in the healthy adult human. | 2001 |
|
Management of calcium oxalate stones. | 2001 |
|
Case report: hand-foot syndrome induced by the oral fluoropyrimidine S-1. | 2001 Apr |
|
Do breastfed infants need supplemental vitamins? | 2001 Apr |
|
Non-pregnant circulatory volume status predicts subsequent pregnancy outcome in normotensive thrombophilic formerly preeclamptic women. | 2001 Apr |
|
Homocysteine levels in patients treated with lipid apheresis: effect of a vitamin therapy. | 2001 Aug |
|
Homocysteine, fibrinogen, and lipoprotein(a) levels are simultaneously reduced in patients with chronic renal failure treated with folic acid, pyridoxine, and cyanocobalamin. | 2001 Feb |
|
A modified dialyzer with vitamin E and antioxidant defense parameters. | 2001 Feb |
|
Effects of long-term parenteral administration of vitamin B6 on B6 status and some aspects of the glucose and protein metabolism of early-weaned piglets. | 2001 Jan |
|
The expert witness. Neither Frye nor Daubert solved the problem: what can be done? | 2001 Jan-Mar |
|
Does lowering plasma homocysteine reduce vascular disease risk? | 2001 Jul |
|
Influence of vitamin-optimized plasma homocysteine cutoff values on the prevalence of hyperhomocysteinemia in healthy adults. | 2001 Jun |
|
Impaired heme binding and aggregation of mutant cystathionine beta-synthase subunits in homocystinuria. | 2001 Jun |
|
A general family of distributions for longitudinal dependence with special reference to event histories. | 2001 Jun 15 |
|
Low dietary folate intake is associated with an excess incidence of acute coronary events: The Kuopio Ischemic Heart Disease Risk Factor Study. | 2001 Jun 5 |
|
Occupational and systemic contact dermatitis with photosensitivity due to vitamin B6. | 2001 Mar |
|
[Behavioral disorders after treatment with isoniazid]. | 2001 May |
|
Disposition of homocysteine in subjects heterozygous for homocystinuria due to cystathionine beta-synthase deficiency: relationship between genotype and phenotype. | 2001 May 1 |
|
Plasma total cysteine as a risk factor for vascular disease: The European Concerted Action Project. | 2001 May 29 |
|
Application of liquid chromatography to the simultaneous determination of acetylsalicylic acid, caffeine, codeine, paracetamol, pyridoxine, and thiamine in pharmaceutical preparations. | 2001 May-Jun |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/pyridoxine.html
Usual Adult Dose for Dietary Supplement
Pyridoxine Deficiency:
10 to 25 mg/day orally, IM, or IV for 3 weeks followed by 2 to 5 mg/day from a multivitamin product.
Usual Adult Dose for Anemia
Sideroblastic, hereditary: 200 to 600 mg orally daily. If adequate response obtained, dose may be decreased to 30 to 50 mg orally daily.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11605018
Pyridoxine (5 mmol/l) caused complete inhibition of microvessel outgrowth in rat aortic rings
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:46:33 GMT 2025
by
admin
on
Mon Mar 31 17:46:33 GMT 2025
|
Record UNII |
KV2JZ1BI6Z
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LOINC |
26915-9
Created by
admin on Mon Mar 31 17:46:33 GMT 2025 , Edited by admin on Mon Mar 31 17:46:33 GMT 2025
|
||
|
LOINC |
2900-9
Created by
admin on Mon Mar 31 17:46:33 GMT 2025 , Edited by admin on Mon Mar 31 17:46:33 GMT 2025
|
||
|
NDF-RT |
N0000192800
Created by
admin on Mon Mar 31 17:46:33 GMT 2025 , Edited by admin on Mon Mar 31 17:46:33 GMT 2025
|
||
|
EU-Orphan Drug |
EU/3/16/1673
Created by
admin on Mon Mar 31 17:46:33 GMT 2025 , Edited by admin on Mon Mar 31 17:46:33 GMT 2025
|
||
|
LIVERTOX |
1035
Created by
admin on Mon Mar 31 17:46:33 GMT 2025 , Edited by admin on Mon Mar 31 17:46:33 GMT 2025
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
27
Created by
admin on Mon Mar 31 17:46:33 GMT 2025 , Edited by admin on Mon Mar 31 17:46:33 GMT 2025
|
||
|
LIVERTOX |
NBK548710
Created by
admin on Mon Mar 31 17:46:33 GMT 2025 , Edited by admin on Mon Mar 31 17:46:33 GMT 2025
|
||
|
DSLD |
3308 (Number of products:6)
Created by
admin on Mon Mar 31 17:46:33 GMT 2025 , Edited by admin on Mon Mar 31 17:46:33 GMT 2025
|
||
|
DSLD |
3377 (Number of products:257)
Created by
admin on Mon Mar 31 17:46:33 GMT 2025 , Edited by admin on Mon Mar 31 17:46:33 GMT 2025
|
||
|
WHO-ATC |
J04AM08
Created by
admin on Mon Mar 31 17:46:33 GMT 2025 , Edited by admin on Mon Mar 31 17:46:33 GMT 2025
|
||
|
FDA ORPHAN DRUG |
334311
Created by
admin on Mon Mar 31 17:46:33 GMT 2025 , Edited by admin on Mon Mar 31 17:46:33 GMT 2025
|
||
|
LOINC |
75043-0
Created by
admin on Mon Mar 31 17:46:33 GMT 2025 , Edited by admin on Mon Mar 31 17:46:33 GMT 2025
|
||
|
NCI_THESAURUS |
C1334
Created by
admin on Mon Mar 31 17:46:33 GMT 2025 , Edited by admin on Mon Mar 31 17:46:33 GMT 2025
|
||
|
WHO-VATC |
QA11HA02
Created by
admin on Mon Mar 31 17:46:33 GMT 2025 , Edited by admin on Mon Mar 31 17:46:33 GMT 2025
|
||
|
CFR |
21 CFR 102.23
Created by
admin on Mon Mar 31 17:46:33 GMT 2025 , Edited by admin on Mon Mar 31 17:46:33 GMT 2025
|
||
|
LOINC |
39786-9
Created by
admin on Mon Mar 31 17:46:33 GMT 2025 , Edited by admin on Mon Mar 31 17:46:33 GMT 2025
|
||
|
WHO-ATC |
A11HA02
Created by
admin on Mon Mar 31 17:46:33 GMT 2025 , Edited by admin on Mon Mar 31 17:46:33 GMT 2025
|
||
|
DSLD |
2695 (Number of products:1886)
Created by
admin on Mon Mar 31 17:46:33 GMT 2025 , Edited by admin on Mon Mar 31 17:46:33 GMT 2025
|
||
|
DSLD |
110 (Number of products:1286)
Created by
admin on Mon Mar 31 17:46:33 GMT 2025 , Edited by admin on Mon Mar 31 17:46:33 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000080848
Created by
admin on Mon Mar 31 17:46:33 GMT 2025 , Edited by admin on Mon Mar 31 17:46:33 GMT 2025
|
PRIMARY | |||
|
KV2JZ1BI6Z
Created by
admin on Mon Mar 31 17:46:33 GMT 2025 , Edited by admin on Mon Mar 31 17:46:33 GMT 2025
|
PRIMARY | |||
|
2216
Created by
admin on Mon Mar 31 17:46:33 GMT 2025 , Edited by admin on Mon Mar 31 17:46:33 GMT 2025
|
PRIMARY | |||
|
200-603-0
Created by
admin on Mon Mar 31 17:46:33 GMT 2025 , Edited by admin on Mon Mar 31 17:46:33 GMT 2025
|
PRIMARY | |||
|
16709
Created by
admin on Mon Mar 31 17:46:33 GMT 2025 , Edited by admin on Mon Mar 31 17:46:33 GMT 2025
|
PRIMARY | |||
|
759148
Created by
admin on Mon Mar 31 17:46:33 GMT 2025 , Edited by admin on Mon Mar 31 17:46:33 GMT 2025
|
PRIMARY | |||
|
684879
Created by
admin on Mon Mar 31 17:46:33 GMT 2025 , Edited by admin on Mon Mar 31 17:46:33 GMT 2025
|
PRIMARY | |||
|
CHEMBL1364
Created by
admin on Mon Mar 31 17:46:33 GMT 2025 , Edited by admin on Mon Mar 31 17:46:33 GMT 2025
|
PRIMARY | |||
|
DTXSID4023541
Created by
admin on Mon Mar 31 17:46:33 GMT 2025 , Edited by admin on Mon Mar 31 17:46:33 GMT 2025
|
PRIMARY | |||
|
1054
Created by
admin on Mon Mar 31 17:46:33 GMT 2025 , Edited by admin on Mon Mar 31 17:46:33 GMT 2025
|
PRIMARY | |||
|
m9365
Created by
admin on Mon Mar 31 17:46:33 GMT 2025 , Edited by admin on Mon Mar 31 17:46:33 GMT 2025
|
PRIMARY | Merck Index | ||
|
C62619
Created by
admin on Mon Mar 31 17:46:33 GMT 2025 , Edited by admin on Mon Mar 31 17:46:33 GMT 2025
|
PRIMARY | |||
|
PYRIDOXINE
Created by
admin on Mon Mar 31 17:46:33 GMT 2025 , Edited by admin on Mon Mar 31 17:46:33 GMT 2025
|
PRIMARY | |||
|
SUB10168MIG
Created by
admin on Mon Mar 31 17:46:33 GMT 2025 , Edited by admin on Mon Mar 31 17:46:33 GMT 2025
|
PRIMARY | |||
|
42954
Created by
admin on Mon Mar 31 17:46:33 GMT 2025 , Edited by admin on Mon Mar 31 17:46:33 GMT 2025
|
ALTERNATIVE | |||
|
D011736
Created by
admin on Mon Mar 31 17:46:33 GMT 2025 , Edited by admin on Mon Mar 31 17:46:33 GMT 2025
|
PRIMARY | |||
|
KV2JZ1BI6Z
Created by
admin on Mon Mar 31 17:46:33 GMT 2025 , Edited by admin on Mon Mar 31 17:46:33 GMT 2025
|
PRIMARY | |||
|
27306
Created by
admin on Mon Mar 31 17:46:33 GMT 2025 , Edited by admin on Mon Mar 31 17:46:33 GMT 2025
|
PRIMARY | |||
|
2836
Created by
admin on Mon Mar 31 17:46:33 GMT 2025 , Edited by admin on Mon Mar 31 17:46:33 GMT 2025
|
PRIMARY | |||
|
65-23-6
Created by
admin on Mon Mar 31 17:46:33 GMT 2025 , Edited by admin on Mon Mar 31 17:46:33 GMT 2025
|
PRIMARY | |||
|
SUB126944
Created by
admin on Mon Mar 31 17:46:33 GMT 2025 , Edited by admin on Mon Mar 31 17:46:33 GMT 2025
|
PRIMARY | |||
|
DB00165
Created by
admin on Mon Mar 31 17:46:33 GMT 2025 , Edited by admin on Mon Mar 31 17:46:33 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT |
MAJOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
Elimination PHARMACOKINETIC |
|
||